Search

Your search keyword '"Heather McVicars"' showing total 3 results
Start Over Author "Heather McVicars" Topic troponin
3 results on '"Heather McVicars"'

1. Cardiac Energetics Before, During, and After Anthracycline-Based Chemotherapy in Breast Cancer Patients Using 31P Magnetic Resonance Spectroscopy: A Pilot Study

Author

Gillian Macnaught, Olga Oikonomidou, Christopher T. Rodgers, William Clarke, Annette Cooper, Heather McVicars, Larry Hayward, Saeed Mirsadraee, Scott Semple, and Martin A. Denvir

Subjects
chemotherapy, breast cancer, cardiac energetics, troponin, ejection fraction, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Purpose: To explore the utility of phosphorus magnetic resonance spectroscopy (31P MRS) in identifying anthracycline-induced cardiac toxicity in patients with breast cancer.Methods: Twenty patients with newly diagnosed breast cancer receiving anthracycline-based chemotherapy had cardiac magnetic resonance assessment of left ventricular ejection fraction (LVEF) and 31P MRS to determine myocardial Phosphocreatine/Adenosine Triphosphate Ratio (PCr/ATP) at three time points: pre-, mid-, and end-chemotherapy. Plasma high sensitivity cardiac troponin-I (cTn-I) tests and electrocardiograms were also performed at these same time points.Results: Phosphocreatine/Adenosine Triphosphate did not change significantly between pre- and mid-chemo (2.16 ± 0.46 vs. 2.00 ± 0.56, p = 0.80) and pre- and end-chemo (2.16 ± 0.46 vs. 2.17 ± 0.86, p = 0.99). Mean LVEF reduced significantly by 5.1% between pre- and end-chemo (61.4 ± 4.4 vs. 56.3 ± 8.1 %, p = 0.02). Change in PCr/ATP ratios from pre- to end-chemo correlated inversely with changes in LVEF over the same period (r = −0.65, p = 0.006). Plasma cTn-I increased progressively during chemotherapy from pre- to mid-chemo (1.35 ± 0.81 to 4.40 ± 2.64 ng/L; p = 0.01) and from mid- to end-chemo (4.40 ± 2.64 to 18.33 ± 13.23 ng/L; p = 0.001).Conclusions: In this small cohort pilot study, we did not observe a clear change in mean PCr/ATP values during chemotherapy despite evidence of increased plasma cardiac biomarkers and reduced LVEF. Future similar studies should be adequately powered to take account of patient drop-out and variable changes in PCr/ATP and could include T1 and T2 mapping.

Published
2021
Full Text
View/download PDF

2. Abstract P1-13-02: Dynamic changes in high-sensitivity cardiac troponin I in response to anthracycline-based chemotherapy-The Cardiac Care Trial pilot data

Author

Peter Henriksen, Morag MacLean, Iain R. Macpherson, Steff Lewis, David E. Newby, Peter Hall, Philip D Adamson, Evangelos Tzolos, Olga Oikonomidou, Nicholas L. Mills, Heather McVicars, and Ninian N. Lang

Subjects
Cancer Research, medicine.medical_specialty, Cardiotoxicity, Chemotherapy, Anthracycline, biology, business.industry, medicine.medical_treatment, Cancer, medicine.disease, Troponin, Breast cancer, Oncology, Internal medicine, medicine, biology.protein, Cardiology, business, Epirubicin, medicine.drug, Blood sampling
Abstract

BACKGROUND Treatment advances have improved cancer-related outcomes and shifted interest towards minimising long-term iatrogenic complications, particularly chemotherapy-related cardiotoxicity. High-sensitivity cardiac troponin I (hs-cTnI) assays accurately quantify very low concentrations of plasma troponin and enable early detection of cardiomyocyte injury prior to development of myocardial dysfunction. The profile of hs-cTnI in response to anthracycline-based treatment has not previously been described. PATIENTS AND METHODS This was a multi-centre prospective observational cohort study. Female patients with newly-diagnosed invasive breast cancer scheduled to receive adjuvant or neo-adjuvant anthracycline-based (epirubicin) chemotherapy were recruited. Blood sampling was performed before, during and 24 hours after each treatment cycle. Plasma hs-cTnI concentrations were measured using the Abbott ARCHITECTSTAT assay (limit of detection 1.2 ng/L, coefficient of variation ≤10% at 4.7 ng/L, 99th centile upper reference limit in women 16 ng/L). RESULTS We recruited 78 women with a mean (standard deviation) age of 53.6 (9.6). The median (IQR) baseline troponin concentration was 1 (1 to 4) ng/L and median (IQR) cumulative epirubicin dose was 394 (300 to 405) mg/m2. Following an initial 33% fall 24 hours following anthracycline dosing (p Citation Format: Olga Oikonomidou, Evangelos Tzolos, Philip D Adamson, Peter S Hall, Iain R MacPherson, Morag MacLean, Steff Lewis, Heather McVicars, David E Newby, Nicholas L Mills, Ninian Lang, Peter A Henriksen. Dynamic changes in high-sensitivity cardiac troponin I in response to anthracycline-based chemotherapy-The Cardiac Care Trial pilot data [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P1-13-02.

Published
2020
Full Text
View/download PDF

3. DYNAMIC CHANGES IN HIGH SENSITIVITY CARDIAC TROPONIN I IN RESPONSE TO ANTHRACYCLINE-BASED CHEMOTHERAPY: A PILOT STUDY FOR THE CARDIAC CARE TRIAL

Author

Steff Lewis, Morag MacLean, Iain R. Macpherson, Heather McVicars, Ninian N. Lang, Nicholas L. Mills, David E. Newby, Olga Oikonomidou, Peter Hall, Philip D Adamson, and Peter Henriksen

Subjects
medicine.medical_specialty, Chemotherapy, Cardiac troponin, Anthracycline, biology, business.industry, medicine.medical_treatment, Early detection, Cancer, macromolecular substances, 030204 cardiovascular system & hematology, musculoskeletal system, medicine.disease, Troponin, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, biology.protein, Cardiology, 030212 general & internal medicine, Myocyte injury, Cardiology and Cardiovascular Medicine, business, Volume concentration
Abstract

Treatment advances have improved cancer outcomes and shifted interest towards minimising iatrogenic complications. High-sensitivity cardiac troponin I (hs-cTnI) assays accurately quantify very low concentrations of troponin and may allow early detection of anthracycline-related myocyte injury.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results